Intranasal Insulin to Prevent Delirium After Hip Fracture Surgery
Optimal Dose of Intranasal Insulin Administration for Reducing Postoperative Delirium Incidence in Older Patients Undergoing Hip Fracture Surgery.
Am J Geriatr Psychiatry . 2025 Aug;33(8):891-900.One hundred fourty four older patients with hip fracture scheduled for unilateral hip arthroplasty or closed reduction and intramedullary nailing under spinal anesthesia were randomized to receive intranasal saline (Control, n=48), intranasal insulin 20U (I-20, n=48), or intranasal insulin 40U (I-40, n=48) given three times (19:00 the day before surgery, 50 minutes before anesthesia, and 19:00 on the day of surgery). The primary outcome was the incidence of postoperative delirium (POD) within postoperative days 1–3, assessed daily with the CAM-ICU; secondary outcomes included day-specific POD incidence, postoperative pain (VAS), cerebrospinal fluid (CSF) glucose and lactate levels, fingertip blood glucose at predefined perioperative time points, and hypoglycemic events. Outcomes were assessed up to 3 days after surgery. Overall, the results of the study revealed that intranasal insulin at both 20U and 40U significantly reduced POD incidence versus placebo without lowering peripheral blood glucose, while 40U modestly increased CSF glucose compared with control. Taken together, these findings suggest that low-dose (20U) intranasal insulin is a simple, non-invasive and potentially optimal regimen to prevent early postoperative delirium in older hip fracture patients without causing hypoglycemia.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics